TP53 and neoplasm: As >95% of high-grade serous ovarian cancers (HGSOC) have a somatic <i>TP53m</i>, combined tumor-based <i>BRCA1/2</i> (<i>tBRCA</i>) and <i>TP53</i> mutation testing (<i>tBRCA/TP53m</i>) may improve the quality of results in somatic <i>BRCAm</i> identification and interpretation of the 'second hit' event, i.e., loss of heterozygosity (LOH).